Earning Analysis
Welcome to our in-depth analysis of Travere Therapeutics Inc(TVTX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Travere Therapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-30 | After Hours | -0.09 | 0.59 | +755.56 | 106.09M | 164.86M | +55.40 | +18.58 | +13.73 |
| FY2025Q2 | 2025-08-06 | After Hours | -0.28 | -0.14 | +50.00 | 100.17M | 114.45M | +14.25 | -1.91 | +0.99 |
| FY2025Q1 | 2025-05-01 | After Hours | -0.39 | -0.47 | -20.51 | 76.86M | 81.73M | +6.34 | +1.88 | -2.55 |
| FY2024Q4 | 2025-02-20 | After Hours | -0.58 | -0.47 | +18.97 | 72.38M | 74.79M | +3.33 | -6.79 | -12.47 |
| FY2024Q3 | 2024-10-31 | Pre-Market | -0.71 | -0.70 | +1.41 | 60.83M | 62.90M | +3.40 | -1.44 | -2.56 |
| FY2024Q2 | 2024-08-01 | - | -0.87 | -0.90 | -3.45 | 52.69M | 54.12M | +2.71 | -3.14 | -11.74 |
| FY2024Q1 | 2024-05-06 | - | -0.98 | -1.76 | -79.59 | 43.62M | 41.37M | -5.14 | +4.63 | +0.64 |
| FY2023Q4 | 2024-02-15 | - | -1.27 | -1.16 | +8.66 | 41.82M | 45.06M | +7.76 | +5.94 | -4.73 |
| FY2023Q3 | 2023-11-07 | - | -1.09 | -1.17 | -7.34 | 56.45M | 37.10M | -34.29 | +8.13 | -14.16 |
| FY2023Q2 | 2023-08-03 | - | -1.16 | -1.13 | +2.59 | 53.60M | 59.70M | +11.37 | -2.05 | -8.24 |
TVTX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Travere Therapeutics Inc reported performance for FY2025Q3, announced on 2025-10-30. The company achieved an EPS of 0.59, compared to analyst estimates of -0.09 by 755.56% . Revenue for the quarter reached 164.86M compared to expectations of 106.09M by 55.40% .
The stock price reacted with a 18.58% one-day change and a 13.73% five-day change following the earnings release. These movements reflect market reaction in Travere Therapeutics Inc growth trajectory and strategic initiatives.
TVTX Earnings Forecast
Looking ahead, Travere Therapeutics Inc(TVTX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 143.04M and an EPS of 0.22.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 19.86%, while EPS estimates have been Revise Downward by -505.83%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 20.74% . These revisions correlate with a 63.26% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Travere Therapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between TVTX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+19.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-505.83%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+20.74%
In Past 3 Month
Stock Price
Go Up
+63.26%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:503.75M
--
EPS Estimate-Annual FY 2025:0.75
—
Stock Price35.33
TVTX Revenue and EPS Performance: A Historical Perspective
Travere Therapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-30,After Hours):
EPS: 0.59 (Actual) vs.-0.09 (Estimate) (755.56%)
Revenue: 164.86M (Actual) vs. 106.09M (Estimate) (55.40%)
Price Reaction: 18.58%(1-Day), 13.73%(5-Day)
FY2025Q2 (2025-08-06,After Hours):
EPS: -0.14 (Actual) vs.-0.28 (Estimate) (50.00%)
Revenue: 114.45M (Actual) vs. 100.17M (Estimate) (14.25%)
Price Reaction: -1.91%(1-Day), 0.99%(5-Day)
FY2025Q1 (2025-05-01,After Hours):
EPS: -0.47 (Actual) vs.-0.39 (Estimate) (-20.51%)
Revenue: 81.73M (Actual) vs. 76.86M (Estimate) (6.34%)
Price Reaction: 1.88%(1-Day), -2.55%(5-Day)
Earnings Reaction
The chart below shows how TVTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TVTX sees a -5.67% change in stock price 10 days leading up to the earnings, and a -4.90% change 10 days following the report. On the earnings day itself, the stock moves by +1.52%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 18.58% on the day following the earnings release and then changed by 14.30% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Summary
Positive
2025-10-30
The earnings call highlights strong financial performance and strategic developments. FILSPARI's growth in IgA nephropathy and potential FSGS approval, along with positive REMS adjustments, suggest a positive outlook. The Q&A reveals consistent demand and effective communication strategies. Despite some management vagueness, the overall sentiment is positive, with expectations of revenue growth and strategic expansions. The market reaction is likely positive, considering these factors.
Travere Therapeutics Inc (TVTX) Q2 2025 Earnings Call Summary
Positive
2025-08-06
The earnings call indicates strong financial performance with significant growth in FILSPARI sales and positive reception of new clinical data. The company is proactive in regulatory engagement and market expansion, with anticipated milestone payments enhancing financial flexibility. Despite some uncertainties in FDA timelines and competition, the market penetration potential and strategic investments suggest a positive outlook. The Q&A session did not reveal major risks, and the focus on educating healthcare providers and leveraging clinical data supports sustained growth. Overall, the sentiment leans positive, suggesting a stock price increase of 2% to 8%.
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Summary
Positive
2025-05-01
The earnings call indicates strong financial performance with a 90% YoY growth in net product sales, driven by FILSPARI's demand. Despite increased expenses, net loss has improved significantly. The company expects significant revenue growth and has a strong cash position. Positive market strategy includes upcoming milestone payments and potential market access in Europe. The Q&A session reveals confidence in FDA interactions and market demand, despite some management evasiveness. Overall, the financial health, market strategy, and shareholder return plan are positive indicators for stock price movement.
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Summary
Neutral
2025-02-22
The earnings call presents a mixed picture: strong revenue growth and FILSPARI's successful launch are positive, but significant net losses and lack of shareholder return plans are concerning. The Q&A highlights confidence in FILSPARI despite competition, but also reveals uncertainties, such as guidance delays and financial sustainability. No new partnerships or shareholder incentives were announced, and financial guidance remains vague. Given these factors, a neutral stock price reaction is expected.
Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Summary
Positive
2024-10-31
The earnings call highlights strong financial performance with significant revenue growth and reduced operating cash use. The company's strategic plan includes expanding FILSPARI's addressable market and anticipates regulatory approval soon, which are positive indicators. The Q&A revealed high compliance rates for FILSPARI and potential market expansion, though management's unclear responses about FDA endpoints slightly dampen sentiment. Overall, the positive financials, strategic growth opportunities, and upcoming approvals outweigh concerns, suggesting a positive stock price movement in the short term.
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Summary
Positive
2024-08-03
The earnings call reflects strong financial performance with significant revenue growth and reduced losses. The Q&A highlights positive sentiment from analysts regarding FILSPARI's market potential and regulatory progress. Despite some unclear responses, the overall tone is optimistic, supported by reduced expenses and a solid cash position. The strategic plan indicates confidence in future growth and regulatory milestones, suggesting a positive stock price movement over the next two weeks.
People Also Watch
FAQ
What were the key highlights of TVTX’s latest earnings report for FY2025Q3?
How did TVTX’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for TVTX for 2025/Q4?
How does TVTX’s stock price correlate with earnings forecast revisions?
What should investors expect from TVTX’s next earnings report?